Nexcera Pharma has achieved milestone payments up to USD 694 million (approx. JPY 110.9 billion) in its alliance with Eli Lilly, already factored into earnings guidance for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexcera Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4565-20260409-01.pdf","jir_short_summary":"Nexcera Pharma has achieved milestone payments up to USD 694 million (approx. JPY 110.9 billion) in its alliance with Eli Lilly, already factored into earnings guidance for the fiscal year ending December 2026.","jir_summary":"### Overview of R&D Alliance\nNexcera Pharma Co., Ltd. has achieved the second development milestone in its multi-target research, development, and commercialization alliance with Eli Lilly and Company focused on diabetes and metabolic diseases. This milestone was attained through the identification of GPCR-targeted small molecule compounds using the Company's NxWave\u2122 platform and elucidation of the binding sites based on receptor structural analysis. Eli Lilly will assume responsibility for further development and commercialization.\n\n### Impact on Performance and Future Outlook\nThis milestone entitles us to receive up to USD 694 million (approx. JPY 110.9 billion) in milestone payments in addition to tiered royalties based on global sales. The impact on consolidated results for the fiscal year ending December 2026 has already been incorporated in the earnings guidance disclosed on February 13, 2026, and is disclosed timely as a significant progress in the Company's growth strategy.","jir_financial_highlights":"Milestone Amount: Up to USD 694 million (approx. JPY 110.9 billion) (Unknown)\nImpact on Consolidated Results for FY Dec 2026: Already incorporated in earnings guidance disclosed on February 13, 2026 (Unknown)","jir_category":"","jir_hashtags":"#NexceraPharmaCoLtd, #M_and_A_Alliance, #JapaneseStocks","jir_key_figures":"Maximum Milestone Amount: USD 694 million (approx. JPY 110.9 billion)\nContract Start Year: 2022\nImpact on FY Dec 2026 Earnings Guidance: Incorporated","jir_meta_title":"Nexcera Pharma Achieves Up to USD 694 Million Milestone in Alliance with Eli Lilly","jir_meta_description":"Nexcera Pharma has achieved its second milestone in the metabolic disease R&D alliance with Eli Lilly, expecting milestone income up to USD 694 million (approx. JPY 110.9 billion), already incorporated in the earnings guidance for FY December 2026.","jir_og_title":"Nexcera Pharma Achieves Key Milestone in Alliance with Eli Lilly","jir_og_description":"Nexcera Pharma has reached the second milestone in its research and development alliance with Eli Lilly, anticipating milestone income up to USD 694 million.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-39535","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n